BogenschutzMPForcehimesAAPommyJA. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
2.
GableRS (1993) Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically. Am J Drug Alcohol Abuse19: 263–281.
3.
GableRS (2004) Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction99: 686–696.
4.
GrobCSDanforthALChopraGS. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
5.
HendricksPSThorneCBClarkCB. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol29: 280–288.
6.
IaconoWGMaloneSMMcGueM (2008) Behavioral disinhibition and the development of early-onset addiction: Common and specific influences. Annu Rev Clin Psychol4: 325–348.
7.
JohansenPØKrebsTS (2015) Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol29: 270–279.
8.
JohnsonMWGarcia-RomeuACosimanoMP. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
9.
KotovRGamezWSchmidtF. (2010) Linking “big” personality traits to anxiety, depressive, and substance use disorders: A meta-analysis. Psychol Bull136: 768–821.
10.
MorralARMcCaffreyDFPaddockSM (2002) Reassessing the marijuana gateway effect. Addiction97: 1493–1504.
11.
NesvågRBramnessJGYstromE (2015) The link between use of psychedelic drugs and mental health problems. J Psychopharmacol.
12.
NuttDJKingLANicholsDE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Rev Neurosci14:577–585.
13.
SchistermanEFColeSRPlattRW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology20: 488–495.
14.
VanyukovMMTarterREKirillovaGP. (2012) Common liability to addiction and “gateway hypothesis”: Theoretical, empirical, and evolutionary perspective. Drug Alcohol Depend123: S3-S17.
15.
Verdejo-GarcíaALawrenceAJClarkL (2008) Impulsivity as a vulnerability marker for substance-use disorders: Review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev32: 777–810.
